Cochrane Abstracts
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) for the Treatment of People With Resected Stage I to III Non‐small‐cell Lung Cancer and EGFR Mutation." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation. Accessed December 7, 2024.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation
Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) for the Treatment of People With Resected Stage I to III Non‐small‐cell Lung Cancer and EGFR Mutation [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
ID - 431474
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
